Obesity drugs need more monitoring

Obesity is a major problem in the world today, and no wonder that many scientists and research teams are gearing to get a solution for this problem. In their efforts that are intended to achieve a comprehensive solution, many anti-obesity drugs and programs have been developed. However, their efficiency and potency needs better data about the long-term effects before a more widespread use of these therapies. This has been indicated in a Canadian study.

It is clear that if the potency and efficiency of these drugs and therapies could be proven beyond doubt, the importance will be increased in the future due to the immanent need of these drugs. 

However, the current study has indicated that the data about these anti-obesity drugs and programs is limited and is not comprehensive, which could be used by one and all–the University of Alberta Hospital in the Lancet has stated that data on drugs already in use is limited particularly over cardiovascular outcomes of their use. The study was conducted by a team that analyzed articles published over the last six years on three drugs–sibutramine, orlistat, and rimonabant. It has been found that many doctors use these drugs carefully, as there are no wonder cures, but these drugs can be helpful in certain proper and conducive circumstances.

The team has indicated that there is no data available about the long-term impact of these drugs, and there was also a very little told about the possible side-effects that these drugs can make.

We can clearly see that the research team has raised a good point which is well reasonable and contains some ground–doctors and health specialists do need the proper data about the long-term effects of these drugs, so that they can prescribe these drugs to their patients without any fear of side-effects.